A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

A Proof-of-concept Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03535571

Enrollment

Registered

2018-05-24

Start date

2018-06-05

Completion date

2018-10-23

Last updated

2019-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Energy increase, Energy, Healthy, anti-inflammatory, Open-label, Salmon protein, Natural health product, Dietary supplement

Brief summary

The objective of this study is to evaluate the efficacy of Salmon Protein Hydrolysate Powder (CollaGo®) on energy increase and anti-inflammatory modulation in healthy males and females. Eligible participants will be asked to consume 1 sachet of CollaGo for 128 days and keep a study diary. Assessments will be measured at the randomization visit, and the end of study visit.

Interventions

DIETARY_SUPPLEMENTSalmon Protein Hydrolysate

4g of salmon protein hydrolysate per serving.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1. Healthy male or female, 30-60 years of age 2. Female participant is not of child bearing potential, defined as females who have had a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with \> 1 year since last menstruation) or, Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner (shown successful as per appropriate follow-up) 3. BMI of 18.5 kg/m²-32.5 kg/m² 4. Agrees to comply with study procedures 5. Willing to commit to taking product for 128 days 6. Agrees to provide voluntary, written, informed consent to participate in the study 7. Agrees to maintain normal diet and exercise routine throughout the study 8. Healthy as determined by medical history, medical physical test for good health, and laboratory results

Exclusion criteria

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial 2. Blood donation during or within 30 days of the last study visit 3. Taking any specific energy supplements or vitamins at least 1 month prior to and during the trial as assessed by the QI 4. Unstable weight for the last 2 months prior to the study assessed case by case by QI 5. Individuals on a low protein diet 6. Excessive consumption of alcohol equivalent to \>2 alcoholic drinks/day 7. Use of marijuana assessed case by case by QI 8. Known allergy to the test material's active or inactive ingredients 9. Clinically significant abnormal Physical Examination results at screening 10. Participation in clinical trials in the past 30 days 11. Cognitively impaired and/or unable to give informed consent 12. current cardiovascular disorders or uncontrolled blood pressure will be assessed by QI) 13. Verbal confirmation of history of or current diagnosis of bleeding/blood disorder 14. Verbal confirmation of Type I or Type II diabetes 15. Verbal confirmation of kidney disease 16. Verbal confirmation of history of liver disease 17. Anemia based on hemoglobin and hematocrit at screening 18. Thyroid disease assessed case by case by QI 19. Iron Supplementation 20. Mood stabilizers assessed case by case by QI 21. Energy boosting supplements 22. Individuals on workout supplements 23. Habitual users of energy drinks 24. Melatonin supplementation assessed case by case by QI 25. Autoimmune disease or if immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive) 26. Surgical procedures which may impact the study outcomes within the past 3 months to be assessed by the QI 27. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission will be assessed by the QI for inclusion. 28. Presence or history of neurological disorders or significant psychiatric illness as assessed by QI 29. Any other condition, in the QI's opinion, which may adversely affect the participant's ability to complete the study or its measures or which may pose significant risk to the participant

Design outcomes

Primary

Measure	Time frame	Description
The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	This questionnaire consists of a total of 30 questions that assess vitality and quality of life. The responses for these questions range from 1 to 7, where 1 indicates never or not at all true 4 indicates sometimes or somewhat true and 7 indicates always or very true depending on the item that is assessed by the question. 15 of the 30 questions are positively keyed in which a higher score indicates a better outcome and remaining 15 questions are negatively keyed where a lower score indicates a better outcome. The responses on the negatively keyed questions will be reversed prior to calculating the total score (i.e. a response of 1 will be considered as 7, 2 will be considered as 6, etc.). Total range will be 30-210, where a higher total score indicates a better outcome and a lower total score indicates a worse outcome.

Secondary

Measure	Time frame	Description
Change From Baseline to Day 128 in Relative Expression of 84 Stress Genes After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	Evaluated by oxidative stress-related gene RT Profiler PCR array. Seven of the 84 genes were upregulated, which are highlighted in the results.
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-11 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray.
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-13 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine TGF-Beta After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray
Change From Baseline to Day 128 in Glycated Hemoglobin (HbA1c) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Fasting Glucose After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change in Score of the Hair, Nails, and Skin Self-Assessment Questionnaire After 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	This questionnaire consists of a total of 7 questions that assess the participant's perception on hair (4 questions), nail (1 question) and skin health (2 question). The response to each question can range from 1 to 6 where 1 indicates greatly satisfied and 6 indicates greatly dissatisfied. The range for the total score on this questionnaire is 7-42. Lower total score indicates a better outcome, and higher total score indicates a worse outcome.
Change From Baseline to Day 128 in Red Blood Cell (RBC) Count After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Mean Corpuscular Volume (MCV) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin (MCH) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Mean Corpuscular Hemoglobin Concentration (MCHC) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Hematocrit After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Red Cell Distribution Width (RDW) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Hemoglobin (Hb) After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	—
Change From Baseline to Day 128 in Total Reactive Oxygen Species/Reactive Nitrogen Species Free Radical Activity After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)	Baseline (Day 0) to end-of-study (Day 128)	Assessed by ROS/RNS assay
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-1 Alpha After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-4 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-6 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray
Change From Baseline to Day 128 in Levels of Human Inflammatory Cytokine IL-10 After Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®).	Baseline (Day 0) to end-of-study (Day 128)	Measured by the Multi-Analyte ELISArray

Other

Measure	Time frame
The Effect of a 128-day Supplementation on Blood Pressure	Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Heart Rate	Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Waist Circumference	Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Hip Circumference	Baseline (Day 0) to end-of-study (Day 128)
The Effect of a 128-day Supplementation on Weight	Baseline (Day 0) to end-of-study (Day 128)
The Incidence of Adverse Events Following a 128-day Supplementation	Baseline (Day 0) to end-of-study (Day 128)

Countries

Canada

Participant flow

Participants by arm

Arm	Count
Salmon Protein Hydrolysate (CollaGo) Dose: 1 sachet of CollaGo will be mixed with 100-300 mL of water and consumed daily at breakfast. Salmon Protein Hydrolysate: 4g of salmon protein hydrolysate per serving.	20
Total	20

Baseline characteristics

Characteristic	Salmon Protein Hydrolysate (CollaGo)
Age, Continuous	48.45 years STANDARD_DEVIATION 5.79
Race/Ethnicity, Customized African or African American	2 Participants
Race/Ethnicity, Customized East Asian or South East Asian	3 Participants
Race/Ethnicity, Customized Hispanic or Latino	1 Participants
Race/Ethnicity, Customized Native American	1 Participants
Race/Ethnicity, Customized South American	3 Participants
Race/Ethnicity, Customized Western or Eastern European White	10 Participants
Sex: Female, Male Female	14 Participants
Sex: Female, Male Male	6 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 20
other Total, other adverse events	5 / 20
serious Total, serious adverse events	1 / 20

Outcome results

Primary

The Change From Baseline (Day 0) to End-of-study (Day 128) in Energy Level After a 128-day Supplementation With Collagenic Salmon Protein Hydrolysate Powder (CollaGo®)

This questionnaire consists of a total of 30 questions that assess vitality and quality of life. The responses for these questions range from 1 to 7, where 1 indicates never or not at all true 4 indicates sometimes or somewhat true and 7 indicates always or very true depending on the item that is assessed by the question. 15 of the 30 questions are positively keyed in which a higher score indicates a better outcome and remaining 15 questions are negatively keyed where a lower score indicates a better outcome. The responses on the negatively keyed questions will be reversed prior to calculating the total score (i.e. a response of 1 will be considered as 7, 2 will be considered as 6, etc.). Total range will be 30-210, where a higher total score indicates a better outcome and a lower total score indicates a worse outcome.